Oncology Drugs Market Size, Growth & Forecast to 2020

1
Global Oncology/Cancer Drugs Market Forecast 2013
- 2020
Published Date 24 Feb 2015
No. of pages 159
2
 
Oncology Drugs Market Scenario

• Oncology Drugs Market is Expected to Reach 111.9
  Billion, Globally, by 2020, registering a CAGR of
  7.1 from 2014 to 2020.
• Increase in adoption of combination therapies
  instead of traditional cytotoxic therapies is a
  major factor that contributes to the market
  growth.
• The combinational therapies which include
  targeted therapy and immunotherapy (Biologic
  therapy), is expected to witness 10 surge in
  its market share collectively by 2020.
• Augmentation in the prevalence and incidence rate
  of various cancers, growing popularity of
  biological and targeted modalities, along with
  the patent expiration of major cancer drugs are
  expected to drive the growth of global oncology
  drugs market.
• However, high initial capital investment in new
  drug development, long-term side effects
  associated with chemotherapy, and high cost of
  advanced therapies (targeted and immunotherapies)
  would limit the growth of the market.

3
 
Oncology Drugs Market Key Segments

• Therapeutic Modalities
• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
• Others
• Cancer Types
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Respiratory/Lung Cancer
• Skin Cancer
• Other Cancers

4
 
Oncology Drugs Market is further bifurcated based
on

• The global oncology drugs market is experiencing
  a shift in therapeutic modalities i.e. from
  traditional cytotoxic agents to newly develop
  targeted and immunotherapeutic modalities.
• Tumor cell specificity, an attribute of
  aforementioned modality, has reduced drug
  remission rates and has rendered an enhanced rate
  of survival in cancer patients thus,
  complementing the market growth.
• chemotherapeutic modalities would continue to be
  the leading therapeutic modality segment owing to
  its higher adoption rate and economic pricing.
• Going forward, the demand for the chemotherapy
  modality might confront a negative influence due
  to marginal efficacy and chronic side effects
  such as anemia.
• Amongst these different cancer types, blood
  cancer was the largest revenue generating segment
  in 2015. The growth of blood cancer segment is
  majorly due to the high cost of the drugs used to
  treat blood cancer. 

5
 
Oncology Drugs Market Drivers And Restraints

• Drivers
• Rising incidence and prevalence of various cancer
  types
• Growing importance of biological and targeted
  drug therapies
• Expiration of key patents and Biosimilars impact
• Acquisitions and collaborations bolt-on
  strategies driving the market growth
• Restraints
• High cost of drug development and threat of
  failure
• Adverse effects of anti-cancer drug therapy

6
 
Key Benefits

• Immunotherapy/biological drugs segment expected
  to grow at a double digit CAGR during the
  forecast period and would grow at the fastest
  rate
• Blood cancer is the major revenue generating
  segment in the global oncology drug application
  market however, lung cancer segment is expected
  to grow fastest among all
• Currently, North America garners a major share in
  the oncology drugs market, in terms of market
  size
• Asia Pacific oncology drug market is dominated by
  China and Japan, together contributing to 60 of
  the regional market revenue in 2014

7
 
Oncology Drugs Market By Geography
North America, Europe, Asia Pacific, LAMEA
8
 
Key Players Operating in Oncology Drugs Market

1. Roche diagnostics
2. Novartis AG
3. Celgene Corporation
4. AstraZeneca
5. Johnson Johnson
6. Merck Co.
7. Eli Lilly Co.
8. Amgen Inc.
9. Pfizer
10. GlaxoSmithKline

9
 
Thank You! For More Details
Visit us at
https//www.alliedmarketresearch.com/oncology-canc
er-drugs-market
Follow Us On